EC17 for Intraoperative Imaging in Occult Ovarian Cancer
A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma
The overall prevalence of Ovarian Cancer in the United States according to the US SEER Registry is 182,710 women. Ovarian cancer also has the highest mortality rate of the gynecological cancers. The overall five-year survival rate is 45% and for Stages III and IV it is only 20-25%. The majority of these are aged 50 years or older, but a few girls less than 10 years of age have been diagnosed with ovarian cancer. This risk increases with age and decreases with numbers of pregnancies.
The prognosis for many carcinomas is dependent on the extent of surgical resection. At present, the ability to perform a complete resection with negative margins is limited by the investigator's ability to palpate and visualize the tumor and its borders. In many cases, a more radical resection than necessary is performed in order to provide assurance that negative margins are achieved. This approach may also increase complication rates, as well as short- and long-term morbidity. It is desirable to improve visualization of primary tumors and occult metastases in real time, during surgery. The use of fluorescent probes that recognize cancer-specific antigens, in conjunction with a clinical imaging system, is under investigation.
Ovarian cancer is a prototypic disease for this type of clinical imaging system called intra-operative imaging. Except in Stage IV, the tumors are confined to the pelvis or abdomen and typically involve extensions or implants onto pelvic or abdominal organs or membranes. Tumor debulking surgery is common early in the disease process as many of the tumors can be identified by appearance or feel in the skilled surgeon's hands. The major problems are that tumors can be diffuse and numerous, of various sizes, and often not readily visible in the surgical field.
Over 90-95% of serous ovarian cancers express folate receptor (FR)-alpha, making this receptor an ideal target for marking most ovarian cancers. Folate is the prototypic agonist at the FR-alpha with potential uses for imaging and targeted therapeutic strategies.Chemotherapy does not affect FR-alpha expression in ovarian cancer specimens examined by immunohistochemistry, so prior treatment is unlikely to affect utility of FR-alpha agonists as imaging or therapeutic agents.
研究概览
研究类型
注册 (预期的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Hospital of the University of Pennsylvania
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female subjects 18 years of age and older
- Female subjects of childbearing potential or less than 2 years postmenopausal agree to receive a urinary or serum beta HCG test prior to subject enrollment. Documentation must be acquired for women of menopausal or post-menopausal status prior to subject enrollment if they are below the age of sixty (60).
Primary diagnosis, or at high clinical suspicion, of primary ovarian cancer:
- Patient is scheduled to undergo laparotomy OR
- Patient is scheduled to undergo laparoscopy then pre-authorized laparotomy if cancer is found.
Exclusion Criteria:
1. Known sarcomatous histologies
- Recurrent ovarian cancer
- Known FR-alpha negative cancer
- Planned surgical approach via laparoscopy or robotic (no intention to perform laparotomy)
- History of anaphylactic reactions to Folate-FITC (EC17) or insects
- Pregnancy
- Brain metastases
- Taking compounds that inhibit active transport of organic anions (probenecid)
- Hepatic impairment, as evidenced by greater than 3x the upper limit of normal (ULN) for ALT, AST, or total bilirubin (except for known cases of Gilbert's syndrome), or renal impairment, as evidenced by greater than 1.5x the ULN for BUN or creatinine
- Received study agent in another investigational drug or vaccine trial prior to surgery
At-risk patient populations
- People who would easily be lost to follow up (ex: People who are homeless or alcohol dependent)
- Patients unable to participate in the consent process (children and neonates)
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:EC17注射组
该小组将接受单剂量的 EC17,在手术前输注超过 10 分钟。
然后,在手术过程中,EC-17 将使用研究人员开发的相机进行成像。
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
EC17 和成像系统在 EC-17 给药后 2-4 小时进行的手术中检测 FRA 阳性肿瘤的能力。
大体时间:在注射 EC17 后两到四个小时内
|
在注射 EC17 后两到四个小时内
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The number of participants that will have an adverse reaction to the EC17
大体时间:Day 1-Day 30
|
Day 1-Day 30
|
合作者和调查者
调查人员
- 首席研究员:Sunil Singhal、University of Pennsylvania
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.